INITIAL COMMENTS
|
This report is a result of a supervisory review of the written report of the findings of an on-site licensure inspection that was conducted on April 16-17, 2019, by staff from the Division of Drug and Alcohol Program Licensure. Based on the supervisory review of findings from the on-site inspection, Clear Day Treatment of Westmoreland, was found not to be in compliance with the applicable chapters of 28 PA Code which pertain to the facility. The following deficiencies were identified during this supervisory review:
|
Plan of Correction
|
715.12(1-5) LICENSURE Informed patient consent
A narcotic treatment program shall obtain an informed, voluntary, written consent before an agent may be administered to the patient for either maintenance or detoxification treatment. The following shall appear on the patient consent form:
(1) That methadone and LAAM are narcotic drugs which can be harmful if taken without medical supervision.
(2) That methadone and LAAM are addictive medications and may, like other drugs used in medical practices, produce adverse results.
(3) That alternative methods of treatment exist.
(4) That the possible risks and complications of treatment have been explained to the patient.
(5) That methadone is transmitted to the unborn child and will cause physical dependence.
|
Observations
The facility failed to obtain an informed, written client consent which included risks factors, prior to the the administration of buprenorphine in four of four client records.
Seven client records were reviewed on April 16-17, 2019. Four were reviewed as buprenorphine clients and required an informed written consent. Client records # 1, 2, 3 and 4 did not not document a written consent prior to the administration of buprenorphine.
These findings were reviewed with facility staff during the licensing process.
|
Plan of Correction
As of 6/20/19 The Clinical Director corrected the electronic records system to obtain an informed, voluntary, written consent and the risk factors before an agent is administered to the patient for detoxification and treatment. The Clinical Director will review the patient records weekly to ensure all patients are made aware of risks of being on MAT maintenance. |